证券代码：605077 证券简称：华康股份 公告编号：2023-057 浙江华康药业股份有限公司 第六届董事会第四次会议决议公告 浙江华康药业股份有限公司（以下简称"公司"）第六届董事会第四次会议于 2023 年 8 月 25 日以现场与通讯相结合的方式召开，本次会议通知于 2023 年 8 月 22 日以通讯方式向全体董事发出。本次会议应出席董事 9 名，实际出席董事 9 名。 公司董事长陈德水先生主持会议，本次会议的召集、召开符合《公司法》和《公 司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 （一）通过《关于调整公司向不特定对象发行可转换公司债券方案的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票 为推进本次公司向不特定对象发行可转换公司债券的工作，根据相关法律法 规及规范性文件要求，并结合公司实际情况及股东大会的授权，决定将公司对宁 波中药制药股份有限公司 2,197.64 万元投资按照财务性投资从本次发行的募集 资金总额中扣减，扣减完成后，本次募集资金总额由不超过 132,500.00 万元调整 为不超过 130,302.36 万元。 具体内容详见同日披露的《浙江华康药业股份 ...

股票代码：605077 股票简称：华康股份 公告编号：2023-060 浙江华康药业股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期 回报与填补措施及相关主体承诺（二次修订稿）的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的意 见》（国办发[2013]110 号）、《国务院关于进一步促进资本市场健康发展的若干意 见》（国发[2014]17 号）以及《关于首发及再融资、重大资产重组摊薄即期回报有 关事项的指导意见》（证监会公告[2015]31 号）等文件的有关规定，为保障中小投 资者知情权，维护中小投资者利益，浙江华康药业股份有限公司（以下简称"公司"） 就本次向不特定对象发行可转换公司债券（以下简称"本次发行"）对即期回报摊薄 的影响进行了认真分析，提出了填补被摊薄即期回报的具体措施，相关主体对公司填 补回报措施能够得到切实履行做出了承诺，具体情况如下： 一、本次发行摊薄即期回报对公司主要财务指标的影响 （一）财务指标计算主要假设和说明 以下假 ...

上海证券交易所上市审核委员会于 2023 年 8 月 18 日召开 2023 年第 76 次审 议会议，对浙江华康药业股份有限公司（以下简称"公司"）向不特定对象发行 可转换公司债券的申请进行了审议。根据会议审议结果，公司本次向不特定对象 发行可转换公司债券的申请符合发行条件、上市条件和信息披露要求。 公司本次向不特定对象发行可转换公司债券事项尚需获得中国证券监督管 理委员会（以下简称"中国证监会"）做出同意注册的决定后方可实施，最终能 否获得中国证监会同意注册的决定及其时间尚存在不确定性。公司将根据该事项 的进展情况，严格按照有关法律法规的规定和要求及时履行信息披露义务，敬请 广大投资者注意投资风险。 特此公告。 证券代码：605077 证券简称：华康股份 公告编号：2023-056 浙江华康药业股份有限公司 关于向不特定对象发行可转换公司债券申请 获得上海证券交易所上市审核委员会审议通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司董事会 2023 年 8 月 19 日 ...

国浩律师（杭州）事务所 补充法律意见书（一） 国浩律师（杭州）事务所 关 于 浙江华康药业股份有限公司 向不特定对象发行可转换公司债券 之 补充法律意见书（一） 北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 重庆 苏州 长沙 太原 武汉 贵阳 乌鲁木齐 香港 巴黎 马德里 硅谷 斯德哥尔摩 BEIJING|SHANGHAI|SHENZHEN|HANGZHOU|GUANGZHOU|KUNMING|TIANJIN|CHENGDU|NINGBO|FUZHOU|XI'AN|NANJING|NANNING|JINAN|CHONGQING|SUZHO U|CHANGSHA|TAIYUAN|WUHAN|GUIYANG|URUMQI|HONGKONG|PARIS|MADRID|SILICON VALLEY|STOCKHOLM 浙江省杭州市老复兴路白塔公园 B 区 15 号楼、2 号楼（国浩律师楼） 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejian ...

目 录 | 一、关于融资规模及效益测算………………………………………第 | | 1—33 | 页 | | --- | --- | --- | --- | | 二、关于华和热电及新易盛贸易………………………………… | 第 | 33—75 | 页 | | 三、关于经营情况………………………………………………… | 第 | 75—84 | 页 | | 四、关于财务性投资……………………………………………… | 第 | 85—97 | 页 | | 五、其他 ………………………………………………………… | 第 | 97—110 | 页 | 根据申报材料，1）公司本次拟募集资金不超过 132,500.00 万元，全部用 于"100 万吨玉米精深加工健康食品配料项目"，项目达产后将实现年度营业收 入 518,137.00 万元，税后内部收益率 30.48%，投资回收期 6.89 年。2）截至报 告期末，公司货币资金余额为 104,042.29 万元。 请公司说明：（1）本项目土建工程、设备购置、工程建设其他费用等具体 内容及测算过程，建筑面积、设备购置数量的确定依据，与新增产能的匹配关 系；（2）效益预测中产品价格、成 ...

关于浙江华康药业股份有限公司 向不特定对象发行可转换公司债券 申请文件的审核问询函的回复报告 上海证券交易所： 贵所于 2023 年 5 月 10 日出具的《关于浙江华康药业股份有限公司向不特 定对象发行可转换公司债券申请文件的审核问询》（上证上审（再融资） （2023）299 号）（以下简称"审核问询函"）已收悉。浙江华康药业股份有 限公司（以下简称"华康股份"、"发行人"、"公司"）与东方证券承销保 荐有限公司（以下简称"东方投行"、"保荐机构"、"保荐人"）、天健会 计师事务所（特殊普通合伙）（以下简称"发行人会计师"、"天健会计师事 务所"）、国浩律师（杭州）事务所（以下简称"发行人律师"、"国浩（杭 州）律所"）等相关方，本着勤勉尽责、诚实守信的原则，就审核问询函所提 问题逐条进行了认真讨论、核查和落实，现回复如下，请予审核。 关于回复内容释义和格式等事项的说明： 1、如无特殊说明，本问询函回复中使用的简称或名词释义与《浙江华康药 业股份有限公司向不特定对象发行股票募集说明书》（以下简称"募集说明 书"）中的含义相同。 2、本问询函回复中，若合计数与各分项数值相加之和在尾数上存在差异， 均为四舍五入 ...

之 国浩律师（杭州）事务所 关 于 浙江华康药业股份有限公司 向不特定对象发行可转换公司债券 补充法律意见书（二） 北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 重庆 苏州 长沙 太原 武汉 贵阳 乌鲁木齐 香港 巴黎 马德里 硅谷 斯德哥尔摩 BEIJING|SHANGHAI|SHENZHEN|HANGZHOU|GUANGZHOU|KUNMING|TIANJIN|CHENGDU|NINGBO|FUZHOU|XI'AN|NANJING|NANNING|JINAN|CHONGQING|SUZHOU|CHANGSHA|TAIYUAN|WUHAN|GUIYANG|URUMQI|HONGKONG|PARIS|MADRID|SILICON VALLEY|STOCKHOLM 浙江省杭州市老复兴路白塔公园 B 区 15 号楼、2 号楼（国浩律师楼） 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: ...

浙江华康药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：605077 证券简称：华康股份 公告编号：2023-047 会议召开时间：2023 年 05 月 26 日（星期五）16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 " 路 演 中 心 " （http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 公开征集问题：投资者可于 2023 年 05 月 25 日 16:00 前登录上证路演中 心网站首页点击"提问预征集"栏目或通过公司邮箱（zqb@huakangpharma.com） 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江华康药业股份有限公司（以下简称"公司"）于 2023 年 3 月 24 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2022 年年度报告，并于 2023 年 4 月 28 日发布公司 20 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥650,334,163.57, representing a year-on-year increase of 60.42%[3] - Net profit attributable to shareholders was ¥90,033,156.75, up 79.03% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 116.40%, totaling ¥87,672,019.87[3] - Basic earnings per share rose to ¥0.39, reflecting a 77.17% increase year-on-year[3] - The net profit for Q1 2023 was CNY 89,978,550.72, a significant increase from CNY 50,288,429.20 in Q1 2022, representing an increase of approximately 78.5%[17] - Operating profit for Q1 2023 reached CNY 101,979,479.11, compared to CNY 54,815,228.74 in the same period last year, indicating a growth of about 85.7%[17] - The company reported a total comprehensive income of CNY 89,979,214.76 for Q1 2023, compared to CNY 50,287,441.02 in Q1 2022, reflecting a growth of about 78.5%[18] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.39, up from CNY 0.22 in Q1 2022, representing an increase of approximately 77.3%[18] Cash Flow and Liquidity - The net cash flow from operating activities surged by 180.66%, amounting to ¥51,670,533.07[3] - Cash flow from operating activities for Q1 2023 was CNY 51,670,533.07, a turnaround from a negative cash flow of CNY -64,061,484.66 in Q1 2022[21] - The company's cash and cash equivalents increased to RMB 1,186,951,026.28 as of March 31, 2023, compared to RMB 1,040,422,902.46 at the end of 2022, reflecting a growth of 14.0%[11] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 1,140,146,521.73, compared to CNY 928,703,617.19 at the end of Q1 2022, an increase of about 22.7%[22] - The net cash flow from financing activities for Q1 2023 was CNY 426,235,248.19, compared to CNY 128,189,146.44 in Q1 2022, indicating a significant increase of approximately 232.5%[22] - Investment activities resulted in a net cash outflow of CNY -359,408,777.65 in Q1 2023, a decrease from a net inflow of CNY 573,832,485.89 in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,541,948,953.16, a 16.31% increase from the end of the previous year[4] - Total liabilities increased to RMB 1,785,503,599.69, compared to RMB 1,249,228,256.74 at the end of 2022, marking a rise of 42.8%[13] - The company's equity attributable to shareholders rose to RMB 2,745,844,481.53, up from RMB 2,655,810,660.74 at the end of 2022, reflecting a growth of 3.4%[14] - Non-current assets totaled RMB 2,303,199,300.24, an increase of 30.3% from RMB 1,766,888,449.85 at the end of 2022[12] - Inventory levels rose to RMB 359,692,737.97, up 28.8% from RMB 279,062,063.26 at the end of 2022[12] Operating Costs and Revenue Drivers - Total operating costs for Q1 2023 were RMB 556,148,093.81, up 48.5% from RMB 374,688,211.48 in Q1 2022[14] - The increase in revenue and profit was primarily driven by an increase in sales volume[6] - Total revenue for Q1 2023 reached RMB 650,334,163.57, a significant increase of 60.3% compared to RMB 405,395,609.58 in Q1 2022[14] - Total revenue from sales of goods and services in Q1 2023 was CNY 677,107,721.74, up from CNY 444,431,593.69 in Q1 2022, marking an increase of approximately 52.5%[20] Research and Development - Research and development expenses for Q1 2023 were RMB 19,026,097.74, a decrease of 13.4% from RMB 22,093,773.10 in Q1 2022[14] Non-Recurring Items - The company reported non-recurring gains totaling ¥2,361,136.88 after tax adjustments[6] - The company recorded a foreign exchange loss of CNY -1,892,044.34 in Q1 2023, slightly improved from a loss of CNY -1,988.66 in Q1 2022[22] - The company reported an investment income of RMB 4,199,870.44 for Q1 2023, down from RMB 20,904,917.32 in Q1 2022[14] Return on Equity - The weighted average return on equity increased by 1.29 percentage points to 3.33%[3]

Financial Performance - The company achieved operating revenue of CNY 2,200,023,095.61 in 2022, an increase of 38.02% compared to 2021, driven by a significant rise in overseas sales, which grew by 70.91%[22] - Net profit attributable to shareholders reached CNY 319,277,839.85, reflecting a year-on-year growth of 34.88%[22] - Basic earnings per share increased by 30.84% to CNY 1.4, while diluted earnings per share also stood at CNY 1.4[22] - The weighted average return on equity rose to 12.59%, an increase of 1.46 percentage points from the previous year[22] - The net cash flow from operating activities was CNY 271,977,255.49, showing a slight increase of 2.90% compared to 2021[22] - The company's total assets grew by 29.99% to CNY 3,905,038,917.48 at the end of 2022[22] - The net assets attributable to shareholders increased by 9.09% to CNY 2,655,810,660.74[22] - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 61.95% to CNY 318,299,893.36[22] - The company set an annual target of exceeding 2 billion yuan in revenue and over 20% profit growth, successfully achieving this "double 20" goal[31] Dividend Policy - The company plans to distribute a cash dividend of 6 RMB per 10 shares to all shareholders, totaling approximately 137.07 million RMB, which represents 42.93% of the net profit attributable to shareholders for 2022[5] - The company has established a cash dividend policy, mandating that at least 30% of the distributable profit must be distributed in cash if certain conditions are met[173] - The profit distribution plan allows for a minimum cash dividend of 30% of the distributable profit if the company meets certain conditions, including positive net profit and cash flow[178] - The company has established a three-year shareholder return plan, prioritizing cash dividends and allowing for stock dividends under specific conditions[178] - The total cash dividend amount for the reporting period was 137,074,560 RMB, which accounted for 42.93% of the net profit attributable to ordinary shareholders[183] Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[4] - The board of directors and supervisory board members have all attended the board meeting, ensuring governance integrity[4] - The company has not faced any issues with more than half of the directors being unable to guarantee the authenticity of the annual report[8] - The company ensured compliance with information disclosure regulations, maintaining transparency and accuracy in reporting[146] - The company’s governance practices align with the requirements set by the Company Law and Securities Law, with no significant discrepancies noted[147] - The company has a complete and effective internal control system in place, ensuring compliance and safeguarding assets[186] - There were no significant deficiencies in internal control reported during the period, indicating robust financial reporting practices[186] - The company has established management controls for its subsidiaries, ensuring alignment with overall corporate strategy[187] Risk Management - There are no significant risk events reported during the reporting period, and potential risks have been detailed in the report[9] - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7] - The company has not violated decision-making procedures for providing guarantees[8] - The company faces risks from price fluctuations of its main products, which could impact profit levels due to increased competition and market dynamics[131] - The company is exposed to raw material price volatility, particularly for starch, which could adversely affect profitability if prices rise significantly[132] - The company has a significant portion of its revenue (51.79%) from overseas sales, making it vulnerable to exchange rate fluctuations[137] Research and Development - The company has obtained a total of 246 authorized patents, including 43 invention patents, to strengthen its technological innovation capabilities[34] - The company has implemented a project responsibility system for R&D, focusing on continuous improvement of existing products and processes, as well as the development of new products[48] - The company established a new R&D center to enhance its research capabilities, focusing on new process technologies and product development, including the fermentation process for xylitol[121] - The company aims to strengthen its technology talent pool by recruiting and training skilled personnel to support rapid growth[122] - The company plans to strengthen its technology development and innovation capabilities, improving product development efficiency and technical competitiveness[120] Environmental Responsibility - The company invested approximately 29.99 million yuan in environmental protection during the reporting period[189] - The average daily COD discharge concentration was 94.35 mg/L, with a total COD discharge of 102.62 tons in 2022[191] - The company reported a total nitrogen (TN) discharge of 7.66 tons in 2022, with an average daily TN concentration of 6.44 mg/L[191] - The company generated 52.36 tons of hazardous waste, including nickel-containing waste and waste mineral oil[192] - The company has established a hazardous waste management ledger and signed disposal contracts with qualified companies[192] - The company’s wastewater treatment facilities processed a total of 404.46 tons of COD and 18.6 tons of ammonia nitrogen in 2022[193] - The company is compliant with multiple environmental standards, including GB25461-2010 and GB16297-1996[191] - The company emphasizes clean production and the development of a circular economy, contributing to carbon peak and carbon neutrality goals[199] Market Expansion and Strategy - The company plans to continue expanding its production capacity, particularly in sorbitol and maltitol, to meet increasing customer demand[22] - The company plans to acquire 95% equity in Zhejiang Huahuo Thermal Power Co., Ltd. for 522.5 million yuan to ensure stable steam energy supply for its projects[33] - The company plans to build a 2 million tons per year corn deep processing health food ingredient project in Zhoushan, Zhejiang Province[55] - The company aims to enhance production capacity for core products like xylitol and sorbitol while optimizing production processes to meet market demand[117] - The company plans to leverage e-commerce platforms to expand sales and provide personalized services to a broader range of end consumers[125] Employee Management - The company reported a total of 1,350 employees, with 888 in the parent company and 462 in major subsidiaries[166] - The workforce includes 950 production personnel, 83 sales personnel, 170 technical personnel, 18 financial personnel, and 129 administrative personnel[166] - The company has a training plan in place to enhance employee skills and capabilities, focusing on both internal and external training[168] - The company has a competitive salary structure aimed at attracting and motivating employees, with a focus on rewarding outstanding performance[167] - A multi-layered incentive mechanism will be established, including competitive compensation structures and rewards for innovation, to boost employee motivation and company cohesion[127]